Navigating the Complex Treatment Landscape of Intermediate and Advanced HCC: A Think Tank Activity
CE Information
1.0 CME creditCompletion Time
1 hourAvailable Until
September 26, 2025Posted By
Integrity CENavigate
Overview
Specialties
OncologySubspecialties
Gastroenterology and RadiologyClinical Topics
OncologyWith the accelerated expansion of the treatment landscape of intermediate and advanced hepatocellular carcinoma (HCC), several practical challenges have emerged in clinical practice. An example of this is the challenge of identifying patients with intermediate HCC who would benefit from local-regional treatment with TACE/TARE or a combination approach with TACE/TARE + IO. Multidisciplinary care is critical to optimize outcomes for these patients.
This program features a moderated discussion among a panel of experts: a surgeon, a hepatologist, and a medical oncologist, all involved in the management and treatment of patients with HCC.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement novel first-line regimens, including multimodal combination and sequential treatment strategies, in the treatment of patients with intermediate HCC based on emerging evidence from clinical trials
- Integrate emerging therapies and novel combination regimens in the treatment of patients with advanced HCC to improve treatment outcomes
Speakers
Director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia
Professor of Medicine, Hematology/Oncology
Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Professor of Radiology, Medicine, and Surgery
Vice-Chair, Image-Guided Therapy
Chief, Vascular and Interventional Radiology
Northwestern University
Chicago, Illinois
Professor of Medicine
Chief of Hepatology and Director of Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas
CE Information
This activity offers 1.0 CME credit to attendees.
Accredited by Integrity CE, LLC (ACCME).
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is provided by Integrity CE, LLC.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosures
DISCLOSURE OF CONFLICTS OF INTEREST
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Richard S. Finn, MD
Consultant: AstraZeneca, Bayer, CStone, Eisai, Eli Lilly, Exelixis, Merck, Novartis, Pfizer, Roche/Genentech, Zai Labs
Research Grants: Bayer, Eisai, Eli Lilly, Pfizer, Merck, Roche/Genentech
Michael Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Steering Committees: Astellas, Merck, Renovo Rx
CME Activity: Astellas
Travel: Astellas, Renovo Rx
Stock: Perthera
Riad Salem, MD
Consultant: AstraZeneca, Becton Dickinson, Boston Sciences, Cook, Eisai, Genentech, Siemens, Sirtex, Terumo
Amit Singal, MD, MS
Consultant: AstraZeneca, Bayer, Boston Scientific, Eisai, Exact Sciences, Exelixis, FujiFilm Medical Sciences, Glycotest, HistoSonics, Merck Genentech, Sirtex
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity